专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009095226A2 NUCLEIC ACIDS OF FORMULA (I) (NUGLXMGNNV)A AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENT/ADJUVANT 审中-公开
标题翻译：制剂（I）（NUGLXMGNNV）的核酸及其作为免疫调节剂/调节剂的衍生物
公开(公告)号：WO2009095226A2
公开(公告)日：2009-08-06
申请号：PCT/EP2009000546
申请日：2009-01-28
申请人： CUREVAC GMBH , KRAMPS THOMAS , VOSS SOEHNKE , PROBST JOCHEN , HOERR INGMAR
发明人： KRAMPS THOMAS , VOSS SOEHNKE , PROBST JOCHEN , HOERR INGMAR
IPC分类号： C12N15/09 , A61K39/39 , C12N15/117
CPC分类号： A61K39/39 , A61K2039/53 , A61K2039/55561 , A61K2039/572 , C07H21/00 , C12N15/117 , C12N2310/17 , C12N2310/314 , C12N2310/315 , C12N2320/31
摘要： The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (NuGlXmGnNv)a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.
摘要翻译：本发明涉及通式（I）的核酸：（NuG1XmGnNv）a及其衍生物作为免疫刺激剂/佐剂和含有其的组合物，任选地包含另外的佐剂。本发明还涉及药物组合物或疫苗，其各自含有上述式（I）核酸和/或其衍生物作为免疫刺激剂，以及任选的至少一种另外的药物活性成分，例如，抗原剂。本发明同样涉及药物组合物或疫苗用于治疗癌症疾病，感染性疾病，过敏症和自身免疫疾病等的用途。同样地，本发明包括通式（I）的核酸，：（NuGlXmGnNv）a和/或其衍生物，用于制备用于治疗这些疾病的药物组合物。

2. 发明申请

WO2008083949A3 RNA-CODED ANTIBODY 审中-公开
标题翻译： RNA编码抗体
公开(公告)号：WO2008083949A3
公开(公告)日：2008-09-25
申请号：PCT/EP2008000081
申请日：2008-01-08
申请人： CUREVAC GMBH , HOERR INGMAR , PROBST JOCHEN
发明人： HOERR INGMAR , PROBST JOCHEN
IPC分类号： A61K48/00 , A61K39/395 , C07K16/28 , C07K16/32 , C12N15/13 , C12N15/85
CPC分类号： C07K16/1027 , A61K9/0019 , A61K39/395 , A61K39/39558 , A61K39/40 , A61K39/42 , A61K48/00 , A61K48/005 , A61K48/0066 , A61K48/0075 , A61K2039/505 , A61K2039/51 , A61K2039/53 , C07K16/1018 , C07K16/2803 , C07K16/2863 , C07K16/2887 , C07K16/30 , C07K16/3046 , C07K16/3061 , C07K16/32 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94
摘要： The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, auto-immune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.
摘要翻译：本申请描述了抗体编码，未修饰或修饰的RNA及其用于表达该抗体的用途，用于制备药物组合物，特别是被动疫苗，用于治疗肿瘤和癌症疾病，心血管疾病，传染病，自身免疫疾病，病毒性疾病和单一疾病，例如也在基因治疗。本发明还描述了体外转录方法，使用本发明的RNA和体内方法来表达该抗体的体外方法。

3. 发明申请

WO2008014979A3 NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT 审中-公开
标题翻译：式（I）的核酸：GIXmGn或OR（II）：CIXmCn，特别是免疫刺激剂/助剂
公开(公告)号：WO2008014979A3
公开(公告)日：2008-05-02
申请号：PCT/EP2007006772
申请日：2007-07-31
申请人： CUREVAC GMBH , HOERR INGMAR , PROBST JOCHEN , KETTERER THOMAS , SCHEEEL BIRGIT
发明人： HOERR INGMAR , PROBST JOCHEN , KETTERER THOMAS , SCHEEEL BIRGIT
IPC分类号： C07H21/02 , C12N15/117
CPC分类号： A61K39/39 , A61K2039/55561 , C07H21/02 , C12N15/117 , C12N2310/17 , C12N2310/3515
摘要： The present invention relates to a nucleic acid of the general formula (I): G l X m G n , or (II): C l X m C n , which may be modified by a lipid. The nucleic acid of the invention acts as an immune-stimulating agent inducing the innate immune response. The invention relates further to a pharmaceutical composition (in a first embodiment), each containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). In another embodiment, the inventive nucleic acid is combined with at least one pharmaceutically active component, a pharmaceutically acceptable carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). Accordingly, the presemt invention is directed to a vaccine, which corresponds to a pharmaceutical composition of the invention (second embodiment), wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention relates likewise to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune diseases, allergies or cancer diseases.
摘要翻译：本发明涉及通式（I）的核酸：或者（II）：C（C 1 -C 4）这可能是由脂质修饰的。本发明的核酸充当诱导先天性免疫应答的免疫刺激剂。本发明还涉及药物组合物（在第一个实施方案中），其各自含有根据本发明的免疫刺激剂以及药学活性载体/载体（以及任选的其他辅助物质，添加剂和/或其他辅助剂）。在另一个实施方案中，将本发明的核酸与至少一种药学活性组分，药学上可接受的载体/载体（以及任选的其他辅助物质，添加剂和/或其他辅助剂）组合。因此，本发明针对疫苗，其对应于本发明的药物组合物（第二实施方案），其中药物活性成分诱导特异性免疫应答（例如抗原）。本发明同样涉及本发明的核酸或根据本发明的药物组合物用于治疗感染性疾病，自身免疫性疾病，变态反应或癌症疾病的用途。

4. 发明申请

WO2009046974A2 COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) 审中-公开
标题翻译：治疗肺癌，特别是非小细胞肺癌（NSCLC）的组合物
公开(公告)号：WO2009046974A2
公开(公告)日：2009-04-16
申请号：PCT/EP2008008503
申请日：2008-10-08
申请人： CUREVAC GMBH , BARNER MARIJKE , PROBST JOCHEN , LANDER THOMAS , HOERR INGMAR
发明人： BARNER MARIJKE , PROBST JOCHEN , LANDER THOMAS , HOERR INGMAR
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A61K2039/53 , A61K2039/57 , A61K2039/572 , A61K2039/575 , A61K2039/70
摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.
摘要翻译：本发明涉及包含至少一种RNA（优选mRNA）的活性（免疫刺激）组合物，所述RNA编码能够在哺乳动物中引发（适应性）免疫应答的至少两种（优选不同）抗原。本发明还涉及包含所述活性（免疫刺激性）组合物的疫苗，并涉及所述活性（免疫刺激）组合物（用于制备疫苗）和/或疫苗用于引发治疗肺癌，特别是非小细胞肺癌（NSCLC），其优选选自三种主要亚型鳞状细胞肺癌，腺癌和大细胞肺癌或与其有关的病症。最后，本发明涉及包含活性（免疫刺激性）组合物和/或疫苗的试剂盒，特别是零件试剂盒。

5. 发明申请

WO2006122828A3 OPTIMIZED INJECTION FORMULATION FOR RNA 审中-公开
标题翻译：改进的注射制剂的mRNA
公开(公告)号：WO2006122828A3
公开(公告)日：2007-05-10
申请号：PCT/EP2006004784
申请日：2006-05-19
申请人： CUREVAC GMBH , HOERR INGMAR , PASCOLO STEVE
发明人： HOERR INGMAR , PASCOLO STEVE
IPC分类号： A61K47/02 , A61K9/00 , A61K31/7088 , A61K47/12 , A61K47/48 , C12N15/87
CPC分类号： A61K39/00 , A61K9/0019 , A61K31/7088 , A61K31/7105 , A61K47/02 , A61K47/12 , A61K48/0008 , A61K48/005 , A61K2039/53
摘要： The invention relates to the use of RNA and an aqueous injection buffer which contains a sodium salt, a calcium salt and optionally a potassium salt and optionally lactate, for producing an RNA injection solution for increasing RNA transfer into and/or RNA translation in a host organism. The invention also relates to an RNA injection solution and to methods for increasing RNA transfer and/or RNA translation of RNA in vivo and in vitro.
摘要翻译：本发明涉及使用RNA和含有钠盐，钙盐和任选的钾盐和任选的乳酸盐，用于RNA注射溶液的制备用于增加RNA转移和/或RNA翻译的含水注射缓冲液 /宿主生物体。本发明还涉及一种RNA注射溶液和方法，用于在体内和体外增加RNA的RNA转移和/或RNA翻译。

6. 发明申请

WO03051401A3 STABILISED MRNA TUMOUR VACCINE 审中-公开
标题翻译：稳定化MRNA肿瘤疫苗
公开(公告)号：WO03051401A3
公开(公告)日：2003-12-18
申请号：PCT/EP0214577
申请日：2002-12-19
申请人： CUREVAC GMBH , HOERR INGMAR , VON DER MUELBE FLORIAN , PASCOLO STEVE
发明人： HOERR INGMAR , VON DER MUELBE FLORIAN , PASCOLO STEVE
IPC分类号： A61K38/19 , A61K39/00 , A61P35/04
CPC分类号： A61K39/0011 , A61K9/0021 , A61K38/193 , A61K48/00 , A61K2039/53 , A61K2039/54 , A61K2039/55522 , A61K2039/572 , A61K2039/70 , A61K2300/00
摘要： The invention relates to a pharmaceutical composition comprising at least one mRNA, which contains at least one region that codes for an antigen from a tumour, combined with an aqueous solvent and preferably with a cytokine, e.g. GM-CSF. The invention also relates to a method for producing the pharmaceutical composition. The inventive pharmaceutical composition is used in particular for the treatment and/or prophylaxis of cancer.
摘要翻译：本发明涉及包含至少一种mRNA，其包括用于从肿瘤区域中的至少一种抗原的至少一种编码，在结合的水性溶剂，优选的细胞因子，例如药物组合物。GM-CSF，以及用于所述药物的制备方法组成。本发明的药物组合物特别用于对抗癌症的治疗和/或预防。

7. 发明申请

WO2008052770A3 (BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN 审中-公开
标题翻译：（碱基）修饰的RNA，用于增加蛋白质的表达
公开(公告)号：WO2008052770A3
公开(公告)日：2008-12-11
申请号：PCT/EP2007009469
申请日：2007-10-31
申请人： CUREVAC GMBH , HOERR INGMAR , VON DER MUELBE FLORIAN
发明人： HOERR INGMAR , VON DER MUELBE FLORIAN
IPC分类号： A61K39/00 , A61K48/00 , C12N15/67
CPC分类号： C12N15/67 , A61K39/00 , A61K48/00 , C12N15/85 , C12N2830/50
摘要： The present application describes a base-modified RNA and the use thereof for increasing the expression of a protein and for the preparation of a pharmaceutical composition, especially a vaccine, for the treatment of tumours and cancer diseases, heart and circulatory diseases, infectious diseases, autoimmune diseases or monogenetic diseases, for example in gene therapy. The present invention further describes an in vitro transcription method, in vitro methods for increasing the expression of a protein using the base-modified RNA, and an in vivo method.
摘要翻译：本申请描述了碱基修饰的RNA及其用于增加蛋白质表达的用途以及用于制备用于治疗肿瘤和癌症疾病，心脏和循环系统疾病，感染性疾病，自身免疫疾病或单基因疾病，例如在基因治疗中。本发明进一步描述了体外转录方法，使用碱基修饰的RNA增加蛋白质表达的体外方法，以及体内方法。

8. 发明申请

WO03059381A2 IMMUNOGENIC PREPARATIONS AND VACCINES ON THE BASIS OF RNA 审中-公开
标题翻译：基于RNA的免疫制备和疫苗
公开(公告)号：WO03059381A2
公开(公告)日：2003-07-24
申请号：PCT/EP0300497
申请日：2003-01-20
申请人： CUREVAC GMBH , PASTEUR INSTITUT , INST NAT SANTE RECH MED , GENETHON III , PASCOLO STEVE CYRIL , HOERR INGMAR , RAMMENSEE HANS-GEORG , VON DER MUELBE FLORIAN , MICHEL MARIE-LOUISE , FIRAT HUESEYIN , LEMONNIER FRANCOIS ALBERT
发明人： PASCOLO STEVE CYRIL , HOERR INGMAR , RAMMENSEE HANS-GEORG , VON DER MUELBE FLORIAN , MICHEL MARIE-LOUISE , FIRAT HUESEYIN , LEMONNIER FRANCOIS ALBERT
IPC分类号： A61K39/21 , A61K39/29 , A61K48/00 , A61P31/00 , A61P31/18 , A61P31/20 , C07K14/02 , C07K14/16 , A61K39/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , A61K39/29 , A61K39/292 , A61K48/00 , A61K2039/53 , A61K2039/55516 , A61K2039/55522 , C12N2730/10122 , C12N2730/10134 , C12N2740/16022 , C12N2740/16034 , C12N2770/24222 , C12N2770/24234
摘要： The present invention relates to the field of vaccination and immune stimulation by the use of nucleic acids, in particular RNA, coding for one or more antigens of pathogenic micro organisms.
摘要翻译：本发明涉及通过使用编码一种或多种病原微生物抗原的核酸，特别是RNA来进行疫苗接种和免疫刺激的领域。

9. 发明申请

WO2007095976A3 ADJUVANT IN THE FORM OF A LIPID-MODIFIED NUCLEIC ACID 审中-公开
标题翻译：佐剂在脂质 - 修饰的核酸的FORM
公开(公告)号：WO2007095976A3
公开(公告)日：2007-11-01
申请号：PCT/EP2006008321
申请日：2006-08-24
申请人： CUREVAC GMBH , HOERR INGMAR , KETTERER THOMAS , PASCOLO STEVE
发明人： HOERR INGMAR , KETTERER THOMAS , PASCOLO STEVE
IPC分类号： C07H21/00 , A61K39/39
CPC分类号： A61K39/39 , A61K31/355 , A61K31/7088 , A61K2039/55511 , A61K2039/55555 , A61K2039/55561 , A61K2039/55572 , C07H21/00
摘要： The invention relates to an immunostimulant adjuvant in the form of a lipid-modified nucleic acid, optionally in combination with other adjuvants. The invention also relates to a pharmaceutical preparation and a vaccine, each of which contains an immunostimulant adjuvant according to the invention, at least one active agent and, optionally, a pharmaceutically suitable support and/or other auxiliary agents and additives and/or other adjuvants. Furthermore, the invention relates to the use of the pharmaceutical composition and the vaccines for the treatment of infectious diseases or cancer diseases. The present invention additionally relates to the use of the immunostimulant adjuvant for producing a pharmaceutical composition for the treatment of cancer diseases or infectious diseases.
摘要翻译：本发明涉及一种脂质修饰的核酸的形式的免疫刺激佐剂，任选地与其它佐剂组合。本发明进一步涉及一种药物组合物和疫苗，根据本发明，至少一种活性成分和任选的药学上可接受的载体和/或其它助剂和添加剂和/或其它佐剂各自含有免疫刺激佐剂。本发明还涉及使用本发明的药物组合物和本发明的用于治疗感染性疾病或癌症疾病的疫苗。此外，本发明包括根据本发明用于制备用于治疗癌症或感染性疾病的治疗的药物组合物中使用的免疫刺激佐剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式